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Molecular Minimal Residual Disease in Acute Myeloid Leukemia
To the Editor: Jongen-Lavrencic and colleagues (March 29 issue) 1 highlight the clinical usefulness of a next-generation sequencing panel to identify minimal residual disease in patients with acute myeloid leukemia (AML) during complete remission. The authors found that the detection of nonclonal hematopoiesis-associated mutations (non-DTA mutations, or those not involving DNMT3A, TET2, or ASXL1) during complete remission predicted a poor prognosis; however, these findings are called into question by the considerable rate of false negative results of next-generation sequencing.
In Figure 3 of the article, available at NEJM.org, the rate of false negative results with next-generation sequencing (i.e., a negative result on nextgeneration sequencing and a positive result on multiparameter flow cytometry) was 12.1% (among 41 of 340 patients). Thus, next-generation sequencing had a disconcertingly high false negative rate of detection of non-DTA mutations during complete remission. Given that patients with negative results on next-generation sequencing and positive results on multiparameter flow cytometry have a worse prognosis than those with negative results on both tests, the data shown in Figure 2 of the article are called into question by the false negative results with nextgeneration sequencing. In that figure, next-generation sequencing was used to stratify patients according to detection or no detection of non-DTA mutations during complete remission.
Thus, it is likely that a considerable number of patients in the "no detection of non-DTA mutation" category were mistakenly classified because of a false negative result on next-generation sequencing. Do the authors have a sense of how many patients in this group had minimal residual disease that was detected by means of multiparameter flow cytometry? Bryan C. Ulrich, B.A.
